The 6 analysts offering 12-month price forecasts for Trevi Therapeutics Inc have a median target of 7.50, with a high estimate of 9.00 and a low estimate of 6.00. The median estimate represents a +563.72% increase from the last price of 1.13.
The current consensus among 6 polled investment analysts is to Buy stock in Trevi Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.11
Reporting Date Mar 20
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.